logo Hematology/Oncology Research Studies: Open for Enrollment Date: 05/27/20


NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes

NCT#/Phase: N/A
Phase 2
IRB#: 2017-095i
Description: This is a phase 2 trial of palbociclib in children with relapsed or refractory solid tumors (including non-Hodgkin lymphomas, histiocytoses and CNS) harboring specified genomic alterations in the cyclinD-cdk4/6-INK4a-Rb pathway, including CDK4 or CDK6 amplification and CCND1, CCND2, or CCND3 amplification, along with positive Rb expression by immunohistochemistry.
Inclusion: Individuals who are between 12 months and 21 years of age and given a therapy assignment to MATCH to APEC1621A
Enrollment Status: Open for enrollment
Sponsor: Children's Oncology Group (COG)
Principal Investigator(s): Carla Golden, MD
Contact(s): Diane Olszewski (510-428-3885 x 3246)
COG CRA Office (510-428-3885 x8334)
Study Link: #

UCSF Benioff Children's Hospital Oakland • 747 52nd Street, Oakland, California 94609 &bull Phone: (510) 428-3000